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Abstract: The present study was aimed at evaluating the antinociceptive and   
anti-inflammatory effects of the ethanol extract from Vernonia condensata leaves in animal 
models, in order to afford a better understanding of these properties. The extract reduced 
the number of abdominal contortions at doses of 100 (51.00 ± 3.00), 200 (42.00 ± 2.98) 
and 400 mg/kg (39.00 ± 4.00). In formalin tests, a significant reduction in the licking time 
(p < 0.01) was observed in the first phase by 25.14 (200 mg/kg = 51.50 ± 4.44) and 31.15% 
(400 mg/kg = 48.00 ± 4.37). The doses of 100 (43.37 ± 5.15), 200 (34.62 ± 4.16) and  
400 mg/kg (28.37 ± 3.98) inhibited (p < 0.001) the second phase. After 60 and 90 min of 
treatment, a dose of 400 mg/kg (10.13 ± 0.39 and 11.14 ± 1.33, respectively) increased the 
latency time. Doses of 200 and 400 mg/kg potentiated the sleeping time induced by 
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diazepam, pentobarbital and meprobamate. The extracts (100, 200 and 400 mg/kg) showed 
anti-inflammatory effects by a decrease in paw edema. The extracts also reduced the 
exudate volume at the doses of 200 and 400 mg/kg. The leukocyte migration had 
significant effect (p < 0.001) at doses of 100, 200 and 400 mg/kg. The completion of 
additional experiments in the investigation of the antinociceptive and anti-inflammatory 
activities of V. condensata allowed a better understanding of the central and peripheral 
mechanisms involved. 
Keywords:  Vernonia condensata; antinociceptive activity; sedative effect;   
anti-inflammatory activity 
 
1. Introduction 
Pain is considered to be one of the most important symptoms associated with inflammatory   
diseases [1,2] and affects a large portion of the population, diminishing their quality of life [3,4]. The 
use of anti-inflammatory drugs has been required to inhibit the mediators of the inflammation, 
preventing the acute response and the development of the chronic process [5]. Therefore, based on 
traditional medicine, search for new natural products from medicinal plants with analgesic and   
anti-inflammatory properties have been encouraged [6–8]. 
Plants of the genus Vernonia (Asteraceae), having approximately 1000 species, are widely 
distributed in most tropical and subtropical countries, and have long been popularly used to treat 
several types of diseases [9]. Vernonia has been used to treat a number of disorders including 
inflammation, malaria, fever, worms, pain, diuresis, cancer, abortion, and various gastro-intestinal 
problems [10,11]. In addition, species of this genus have been studied and their pharmacological 
properties established. For example, V. glabra showed hypotensive effect [12], V. patens demonstrated 
phototoxic, antibacterial and anti-inflammatory activities [13] and V. kotschyana presented 
immunomodulatory activity [14]. V. amygdalina revealed anti-histaminic effect [15] but was not 
hepatotoxic in rats [16]. These activities can be attributed to compounds such as polysaccharides from 
V. kotschyana [14], vernolepin found in V. amygdalina [15] and hesperidin, 3’-methylhesperetin, 
homoesperetin-7-O-rutinoside, sitosterol and stigmasterol identified in V. diffusa [17]. 
Vernonia condensata Baker, one Asteraceae family member, commonly known as figatil or 
necroton, has been traditionally used as analgesic, anti-inflammatory, anti-thermal, antianemics, 
antibacterial, liver tonic, liver toxicity and antiulcerogenic agents [10,11]. Analgesic, anti-inflammatory 
and antiulcerogenic activities of V. condensata, as well as toxicity have been investigated [18–21].  
In these studies, vernonioside B2 demonstrated antinociceptive and anti-inflammatory effect [20]. 
Furthermore, constituents such as saponins, tannins, alkaloids, phenolic compounds and flavonoids 
were detected in the extracts from V. condensata [21]. 
Although antinociceptive and anti-inflammatory activities from V. condensata have been described, 
new essential investigations have been encouraged in order to confirm these evidences and to establish 
the involved mechanisms by methods not yet applied. In this sense, in the present study we investigated Int. J. Mol. Sci. 2011, 12                 
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the antinociceptive, anti-inflammatory and sedative properties of the ethanol extract from V. condensata 
leaves, using appropriate experimental animal models. 
2. Results and Discussion 
2.1. Phytochemistry Screening  
The phytochemical screening results of the ethanol extract from V. condensata leaves showed the 
presence of different types of active constituents such as flavonoids, terpenoids, sterols, coumarins, 
tannins, saponins and volatile oils. 
2.2. Acute Toxicity  
At the doses administered per oral route (p.o.), the ethanol extract from V. condensata leaves   
was not toxic to animals, presenting LD50 up to 3 g/kg. During this experiment, an important feature 
was observed that the mice presented somnolence. The dosage definition in the experiments of 
pharmacological activities was based on the LD50 value. 
2.3. Writhing Response Induced by Acetic Acid in Mice  
Doses of 100 (51.00 ± 3.46; 24.86%), 200 (42.00 ± 2.98; 38.12%) and 400 mg/kg (39.00 ± 4.00; 
42.54%) of V. condensata ethanol extract significantly (p < 0.001) reduced the abdominal contortions 
induced by acetic acid when compared to the control group (67.87 ± 4.14) (Figure 1). 
Figure 1. Effects of the ethanol extract from V. condensata leaves on acetic acid induced 
writhing in mice. Data are mean ± S.E.M. of eight mice. ***P < 0.001 vs. control group.  
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2.4. Effects on Formalin-Induced Nociception in Mice 
The intraplantar injection of formalin promoted a biphasic characteristic response (Figure 2). The 
time spent licking in the first phase (0–5 min) was 66.62 ± 4.76 s and in the second phase (15–30 min) 
was 79.37 ± 4.15 s for the control group. After 60 min of treatment, a significant reduction in the 
licking time (p < 0.01) was observed during the first phase after formalin administration (neurogenic) 
by 25.14 and 31.15% with 200 and 400 mg/kg of extract, respectively (Figure 2). In the second phase, 
the doses of 100, 200 and 400 mg/kg of extract inhibited significantly (p < 0.001) at 45.36, 56.38 and 
64.26%, respectively, when compared to the control. As expected, morphine (1 mg/kg, s.c.) significantly 
reduced the formalin response in both phases. The indomethacin inhibitory effect was observed in the 
second phase. 
Figure 2. Effects of the ethanol extract from V. condensata leaves on formalin-induced 
nociception in mice. First phase = 0–5 min after formalin injection; second   
phase = 15–30 min. Data are mean ± S.E.M. of eight mice. **P < 0.01; ***P < 0.001 vs. 
control group. 
 
2.5. Effects on Hot-Plate Latency Assay in Mice  
The V. condensata ethanol extract increased the latency time of mice exposed to the hot plate test 
(Table 1). After 60 and 90 min of treatment, dose of 400 mg/kg (82.52 and 87.54%, respectively) 
increased significantly (p < 0.001) the latency time in the respective control group. Morphine proved 
to be a potent analgesic, increasing the latency time within the evaluation periods. Naloxone, an opioid 
antagonist, blocked the morphine action but did not alter the antinociceptive effect of the tested extract, 
increasing the latency time at 102.52%. In this assay, we also observed that mice became lethargic. Int. J. Mol. Sci. 2011, 12                 
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Table 1. Effects of the ethanol extract from V. condensata leaves on the latency time of 
mice exposed to the hot plate test. 
Group 
Dose 
(mg/kg) 
Time after drug administration (seconds) 
0 min  30 min  60 min  90 min 
Control  Saline  5.01 ± 0.31 5.56 ± 0.83  5.55 ± 0.47  5.94 ± 0.64 
  100  5.03 ± 0.46 4.88 ± 0.84  5.71 ± 0.40  5.94 ± 0.87 
Ethanol extract  200  5.46 ± 0.54 6.01 ± 0.38  6.85 ± 0.45  7.50 ± 0.77 
  400  5.50 ± 0.67 7.64 ± 0.99  10.13 ± 0.39***  11.14 ± 1.33***
Morphine  1  6.24 ± 0.77 9.77 ± 0.44*** 11.82 ± 0.39***  14.51 ± 0.94***
Naloxone + Morphine  1 + 1  5.57 ± 0.68 9.99 ± 0.96*** 8.24 ± 0.56**  7.01 ± 0.59 
Naloxone + Extract  1 + 400  5.54 ± 0.74 8.39 ± 0.67*  12.16 ± 0.74***  12.03 ± 1.05***
Each value represents the mean ± S.E.M. of 8 mice. *P  < 0.05; **P  < 0.01; ***P  < 0.001 
significantly different from the control group. 
2.6. Effect on Sleeping Time 
The doses of 200 and 400 mg/kg of ethanol extract from V. condensata potentiated the sleeping 
time induced by diazepam (57.7%, 98%, and 156.4%, respectively), pentobarbital (75.4%, 122.9%, 
and 192.6%, respectively) and meprobamate (56.1%, 89.6%, and 124.4%, respectively) (Figure 3). 
Figure 3. Effect of the ethanol extract from V. condensata leaves on sleeping time (min) 
induced by diazepam, pentobarbital and meprobamate in mice. Data are mean ± S.E.M. of 
eight mice. **P < 0.01; ***P < 0.001 vs. control group. 
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2.7. Effects on Carrageenan-Induced Edema in Rats  
The V. condensata ethanol extract anti-inflammatory effect evaluated by the paw edema method 
induced by carrageenan is shown in Table 2. Based on the presented data, the edema inhibition was 
observed 2 h after carrageenan application of doses of 200 (0.51 ± 0.06; 40.00%; p < 0.05) and   
400 mg/kg (0.59 ± 0.07; 30.59%; p < 0.05). Three hours after carrageenan injections, the doses of  
100 (0.73 ± 0.07; p < 0.05), 200 (0.72 ± 0.03; p < 0.05) and 400 mg/kg (0.63 ± 0.04; p < 0.01) reduced 
the respective paw edema (21.50, 22.58 and 32.26%). The paw edema was also inhibited at the doses 
100, 200 and 400 mg/kg 4 h after carrageenan application. In this time, indomethacin reduced the paw 
edema at 50.00%. 
Table 2. Effects of the ethanol extract from V. condensata leaves on the rat paw edema 
induced by carrageenan. 
Group Dose  (mg/kg) 
Volume of hind paw (mL) 
1 h  2 h  3 h  4 h 
Control  Saline  0.65 ± 0.09  0.85 ± 0.09  0.93 ± 0.06  1.10 ± 0.08 
  100  0.42 ± 0.02  0.72 ± 0.03  0.73 ± 0.07 *  0.85 ± 0.05 * 
Ethanol extract  200  0.46 ± 0.04  0.51 ± 0.06 *  0.72 ± 0.03 *  0.70 ± 0.09 ** 
  400  0.45 ± 0.03  0.59 ± 0.07 *  0.63 ± 0.04 **  0.74 ± 0.06 ** 
Indomethacin  10  0.41 ± 0.09  0.43 ± 0.08 ** 0.51 ± 0.08 ***  0.55 ± 0.06 ***
Each value represents the mean ± S.E.M. of 6 rats. * P < 0.05; ** P < 0.01; *** P < 0.001 
significantly different from the control group. 
2.8. Effects on Carrageenan-Induced Pleurisy in Rats  
The anti-inflammatory effect of the V. condensata ethanol extract was confirmed by a decrease in 
exudate volume and leukocyte migration to the pleural cavity of rats. The pleurisy effects 
demonstrated that doses of 200 (1.53 ± 0.07; p < 0.01) and 400 mg/kg (1.20 ± 0.08; p < 0.001) of  
the extract significantly reduced the exudate volume by 17.30 and 35.13%, respectively, when 
compared to the control group (Figure 4). The number of total leukocytes was inhibited significantly  
(p < 0.001) at the doses of 100 (10.18 ± 0.24 × 10
3 cells/mm
3), 200 (9.47 ± 0.10 × 10
3 cells/mm
3) and 
400 mg/kg (8.17 ± 0.14 × 10
3 cells/mm
3) (Figure 5). Indomethacin reduced the exudate volume and the 
leukocyte migration. 
Considering that the use of commercially available analgesic and anti-inflammatory drugs (opioids 
and non-steroidal anti-inflammatory drugs) exerts a wide range of side effects [5], there is currently a 
strong interest in developing new therapeutic agents from natural products [6–8]. Agents that inhibit 
different mediators that are involved in the evolution of inflammatory processes, including pain, are 
especially relevant [2,5]. In this context, studies have been carried out with natural products in models 
of pain and inflammation in order to assess their pharmacological potential, as well as developing new 
therapeutic options [6–8,22,23]. Int. J. Mol. Sci. 2011, 12                 
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Figure 4. Effects of the ethanol extract from V. condensata leaves on pleural exudation in 
carrageenan-induced pleurisy in rats. Data are mean ± S.E.M. of six rats. ** P < 0.01,  
*** P < 0.001 vs. control group. 
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Figure 5. Effects of the ethanol extract from V. condensata leaves on number of leucocytes 
in carrageenan-induced pleurisy in rats. Data are mean ± S.E.M. of six rats. *** P < 0.001 
vs. control group. 
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The phytochemical analyses revealed the presence of flavonoids, tannins, coumarins, saponins, 
alkaloids, glycosides, tannins, triterpenoids and steroidal nucleus. Despite previous descriptions of 
most of these constituents [21], in the present study coumarins and glycosides were detected for the 
first time. A variety of in vitro and in vivo experiments have shown that flavonoids, tannins, triterpenoids 
and other secondary plant metabolites possess analgesic and anti-inflammatory properties [23–25]. 
Vernonioside B2, for example, identified in this plant, may contribute to the observed anti-inflammatory 
and antinociceptive effects of V. condensata [20]. 
The acute toxicity test showed that the V. condensata leaves’ ethanol extract doses determined  
were not toxic to mice, confirming results of earlier studies [19,21]. It is important to mention that the  
largest dose administered (400 mg/kg) is less than the lowest dose applied for determination of the 
LD50 (0.5 g/kg or 500 mg/kg). During the experiment, it was observed that the mice presented 
somnolence, demonstrating a probable sedative effect. 
In this study, we investigated an ethanol extract from V. condensata by classical nociception and 
acute inflammation models. This study demonstrated that ethanol extract produces antinociceptive and 
anti-inflammatory effects in models of nociception (acetic acid-induced abdominal writhing, formalin 
test and hot plate test) and inflammation (paw edema and pleurisy tests), providing a scientific basis to 
explain, in part, the popular use of V. condensata in Brazilian folk medicine. It also suggests that the 
ethanol extract contains bioactive constituents that could be responsible for the observed activities. 
The acetic acid-induced writhing reaction has been largely used as a screening tool for the assessment 
of analgesic or anti-inflammatory properties. According to Collier et al. [26], acetic acid acts indirectly 
by inducing the release of endogenous mediators sensitive to nonsteroidal anti-inflammatory drugs and 
opioids. This substance also promotes an increase in exudates levels of PGE2 and PGF2 (mediators of 
inflammation), bradykinin, substance P and some cytokines (IL-1β, TNF-α, and IL-8) [27]. For this 
experiment, ethanol extract from V. condensata pretreated animals modified the nociceptive response 
induced by acetic acid in a dose-dependent manner. This fact suggests that probably the antinociceptive 
action of extract occurs peripherally, and it also inhibits the release of mediators in response to acetic 
acid. Therefore, the result corroborates previously studies [18,20,21]. 
Formalin-induced nociception was another essential test employed in this study and this classical 
animal model was not applied in the reports made before with V. condensata. It is considered the most 
predictive of acute pain because it causes a local tissue injury to the paw and is also indicative of tonic 
and localized inflammation pain [28]. This test exhibits two distinct phases of the licking response: the 
first phase is characterized by neurogenic pain caused by a direct chemical stimulation of nociceptors, 
and the second phase is characterized by inflammatory pain generated by a combination of stimuli, 
including inflammation of the peripheral tissues and mechanisms of central sensitization.
 In this last 
phase, different chemical mediators are involved, such as excitatory amino acids, neuropeptides, 
PGE2, nitric oxide, and kinins [29]. We observed that when ethanol extract from V. condensata was 
injected 60 min prior to formalin, a significant inhibition of the formalin response was seen during the 
second phase (inflammatory). It is suggested that the early phase is due to a direct effect on 
nociceptors and prostaglandins that do not play an important role during this phase. In contrast, the late 
phase seems to be an inflammatory response that can be inhibited by nonsteroidal anti-inflammatory 
drugs and corticosteroids [28,29]. Taken together, these results revealed a probably similar action to 
the nonsteroidal anti-inflammatory drugs.  Int. J. Mol. Sci. 2011, 12                 
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To distinguish between central and peripheral antinociceptive actions, we extended our studies to 
the hot-plate test because this technique has not been used in previous studies with V. condensata. This 
test is considered to be sensitive to drugs acting at the supraspinal modulation level of the pain 
response [27], suggesting at least a modulatory effect of the extract. In this study, antinociceptive 
action did not depend entirely on the opioid system, because the treatment with naloxone did not 
completely reverse the produced effect [6]. Furthermore, after thermal stimulus, mice showed lethargy, 
indicating a sedative effect, which could explain the analgesic activity independent of opioid action. 
To better understand the somnolence and lethargy by observing signals in the experiments of acute 
toxicity and hot plate test, and to clarify the analgesic activity independent of opioid system activity, 
diazepam, pentobarbital and meprobamate were used to induce sleep in the animals. Benzodiazepines 
act at specific binding sites that are closely linked to γ-aminobutyric acid (GABAA) receptor and 
enhancing the GABA-ergic transmission which might be related to its sedative activity [30]. 
Prolongation of pentobarbital-induced sleeping time might be due to the tranquilizing action as well as 
CNS depressant action related to GABAA receptors [31]. Although the exact mechanism responsible 
for the sedation action of meprobamate is not fully clear, it might be due to CNS depressant action or 
also due to enhancement of GABA-ergic transmission [32]. The ethanol extract from V. condensata 
significantly potentiated the duration of diazepam-, pentobarbital- and meprobamate-induced sleep in 
mice, suggesting probable tranquilizing action as well as CNS depressant action [30–32]. However, the 
responsible compound(s) for the hypnotic effect of V. condensata is not clearly known and could not 
be concluded based on the results of the present study. On the other hand, other plants containing 
compounds such as flavonoids, terpenes and saponins have been found to have hypnotic effects [33]. 
Therefore, we can speculate that these constituents might be responsible for the sedative effect of  
V. condensata since these chemical classes were detected in the present study. Flavonoids with 
anxiolytic and/or antidepressant activities have also been described in numerous plant species used in 
folk medicine to depress the CNS. This effect has been described by their affinity for the central 
benzodiazepine receptors [34]. It could be suggested that flavonoids of the V. condensata contribute to 
the sedative effect of this plant through benzodiazepine receptors. 
The anti-inflammatory effect observed in the formalin test was confirmed in carrageenan-induced 
paw edema in rats, an animal model widely employed for the screening of anti-inflammatory 
compounds. The inflammatory response induced by carrageenan is characterized by the formation of 
marked edema resulting from the release of several mediators such as histamine, serotonin and 
bradykinin; this is subsequently sustained by release of prostaglandins produced by inducible isoforms 
of cyclooxygenase (COX-2) [35–37]. In the present study, oral treatment with the ethanol extract  
from  V. condensata inhibited carrageenan-induced paw edema in rats. This treatment consistently 
attenuated the paw edema induced by carrageenan, as well as by several inflammatory mediators 
known to participate in the carrageenan response, such as bradykinin, histamine, substance P and 
platelet-activating factor [38–41]. This evidence suggests that the anti-inflammatory actions of the 
ethanol extract from V. condensata are related to the inhibition of one or more intracellular signaling 
pathways involved in the effects of these mediators. 
The inflammation model of carrageenan-induced pleurisy was used to gain further insights into the 
anti-inflammatory effects of the ethanol extract from V. condensata [42–44]. Carrageenan-induced 
pleurisy has been used to investigate the mechanisms involved in acute inflammation and also to assess Int. J. Mol. Sci. 2011, 12                 
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the effectiveness of anti-inflammatory drugs [42,45]. As expected, in our experiments intrapleural 
injection of carrageenan caused a marked accumulation of pleural exudate, followed by intense 
migration of inflammatory cells into the pleural cavity. Treatment of rats with the ethanol extract 
significantly reduced the volume of pleural exudate accumulated in response to carrageenan injection 
and also inhibited the migration of leucocytes. 
3. Experimental Section 
3.1. Plant Material and Extraction  
Specimens of Vernonia condensata Baker used in this study were cultivated and collected at   
the Medicinal Garden of the Faculty of Pharmacy, Federal University of Juiz de Fora, in Juiz de  
Fora, State of Minas Gerais, Brazil, in August 2010. The species was identified by Dr. Fátima   
Regina Gonçalves Salimena and a voucher specimen (CESJ number 52943) was deposited in the 
Herbarium of the Federal University of Juiz de Fora, Brazil. Dried and powdered mature leaves   
(465 g) were exhaustively extracted in 95% ethanol (2.5 L) by static maceration for 3 weeks at room 
temperature with renewal of solvent every 2 days. The ethanol extract was filtered and evaporated 
under a rotary evaporator at controlled temperature (50–60 °C). This material was placed in a desiccator 
with silica to yield 27 g. The dried extract was dissolved using 1% DMSO in normal saline for 
pharmacological studies. 
3.2. Chemicals  
Drugs and reagents used in this study (and their sources) were as follows: acetic acid (Vetec 
Química Farm Ltda, Rio de Janeiro, RJ, Brazil), formaldehyde (Reagen Quimibrás Ind. Química S.A., 
Rio de Janeiro, RJ, Brazil), diazepam (União Química Farmacêutica Nacional S/A, Embu-Guaçu, SP, 
Brazil), pentobarbital (Syntec, Cotia, SP, Brazil), morphine hydrochloride (Merck Inc., Whitehouse 
Station, NJ, USA), meprobamate, naloxone and indomethacin (Sigma Chemical Co, St Louis, MI, USA).  
3.3. Phytochemical Screening of the Ethanol Extract  
The screening of chemical constituents was carried out with the ethanol extracts using chemical 
methods and thin-layer chromatography (TLC), according to the methodology suggested by Matos [46], 
including flavonoids, tannins, coumarins, alkaloids, saponins, terpenoids, steroids and volatile oils.  
3.4. Animals 
Male Wistar rats (90–110 days) weighing 200–240 g and male Swiss albino mice (50–70 days) 
weighing 25–30 g were used in the experiments. The animals were provided by the Central Biotery of 
the Federal University of Juiz de Fora. The animals were divided into groups and kept in plastic under 
a 12 h light/12 h dark cycle at room temperature (22 ± 2 °C), with free cages (47 × 34 × 18 cm) access 
to Purina rations and water. Animal care and the experimental protocol followed the principles and 
international guidelines suggested by the Brazilian College of Animal Experimentation (COBEA) and 
were approved by the local ethical committee (protocol number 036/2010). Int. J. Mol. Sci. 2011, 12                 
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3.5. Acute Toxicity  
Groups of ten mice received oral doses of 0.5, 1, 1.5, 2 and 3 g/kg of ethanol extract from   
V. condensata, while the control group received the vehicle (saline). The groups were observed for  
48 h and 50% lethal dose (LD50) was mortality at end of this period was recorded for each group [47]. 
The LD50 determined by probit test using a log plot of percentage death versus dose [48]. 
3.6. Acetic Acid-Induced Writhing Test 
The acetic-acid writhing test is used for the evaluation of analgesic activity [26]. Mice (n = 8 per 
group) were injected (i.p.) with 0.6% acetic acid (10 mL/kg body weight), and the intensity of 
nociception was quantified by counting the total number of writhes that occurred between 10 and  
30 min after injection. Animals received ethanol extract (100, 200 or 400 mg/kg, p.o.) or sterile saline 
(control group, 0.9%, w/v) 60 min before acetic acid injection. Indomethacin (10 mg/kg, p.o.) and 
morphine (1 mg/kg, s.c.) were administered 60 min before acetic acid as reference compounds. 
3.7. Formalin Test 
Twenty microliters of 1% formalin was administered i.pl. in the mouse’s right paw. The licking 
time was then recorded from 0 to 5 min (phase 1, neurogenic) and from 20 to 25 min (phase 2, 
inflammatory) after formalin administration [29,49]. Mice were then treated (p.o.) with extract (100, 
200 or 400 mg/kg) or sterile saline (0.9%) 60 min before formalin injection. Indomethacin (10 mg/kg, 
p.o.) and morphine (1 mg/kg, s.c.) were also administered 60 min before the formalin injection and 
used as reference compounds. 
3.8. Hot Plate Test 
Animals were placed on a hot-plate (Model LE 7406, Letica Scientific Instruments, Barcelona, 
Spain) heated at 55 ± 1 °C [50]. Three groups of mice (n = 8) were treated p.o. with ethanol extract 
(100, 200 or 400 mg/kg; 0.1 mL per 10 g body weight); the control group received sterile saline  
(10 mL/kg). Measurements were performed at time 0, 30, 60 and 90 min after drug administration, 
with a cut-off time of 40 s to avoid lesions to the animals’ paws. The effect of pretreatment with 
naloxone (1 mg/kg, subcutaneously) on the analgesia produced by the ethanol extract (400 mg/kg) was 
determined in a separate group of animals. Morphine (1 mg/kg, subcutaneously), in the absence and 
presence of naloxone treatment, was used as a reference. 
3.9. Effect on Sleeping Time in Mice 
Mice were divided into 4 groups, each group containing 8 animals. The animals of group I served as 
the control (normal saline, 0.9 % (w/v) NaCl, 5 mL/kg); groups II, III, and IV received ethanol extract 
at the doses (100 mg/kg, 200 mg/kg and 400 mg/kg, respectively). Normal saline and the extracts were 
applied orally 60 min prior to the administration of pentobarbital sodium (40 mg/kg, i.p.), diazepam  
(3 mg/kg, i.p.) and meprobamate (100 mg/kg, i.p.). The sleeping time was noted by recording the 
interval between the losses and regaining of righting reflex [51]. Int. J. Mol. Sci. 2011, 12                 
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3.10. Carrageenan-Induced Rat Paw Edema 
Anti-inflammatory activity was assessed on the basis of inhibition of paw edema induced by the 
injection of 0.1 mL of 2% carrageenan (an edematogenic agent) into the subplantar region of the right 
hind paw of the rat [52]. Male Wistar rats were divided into groups of six animals which received p.o. 
doses of extract (100, 200 and 400 mg/kg; 0.1 mL per 10 g body weight), saline or indomethacin  
(10 mg/kg) 1 h before the injection of carrageenan. In the left paw, used as a control, 0.1 mL of sterile 
saline was injected. 1, 2, 3 and 4 h after injection of carrageenan, the measure of edema was made by 
the difference between the volume displaced by the right paw and the left paw using a plethysmometer 
(model LE 7500, Letica Scientific Instruments, Barcelona, Spain). 
3.11. Carrageenan-Induced Pleurisy in Rats 
Pleurisy was induced in male Wistar rats by intrapleural administration of 0.5 mL 2% carrageenan 
suspension in saline solution between the third and fifth ribs on the right side of the mediastinum [42]. 
Extract (100, 200 and 400 mg/kg), saline or indomethacin (10 mg/kg) p.o. were given 60 min before 
injection of the irritant. Animals were killed 4 h after carrageenan injection, and the skin and pectoral 
muscles were retracted. A longitudinal incision was made between the third and fifth ribs on each side 
of the mediastinum. The exudate was collected and transferred to a 15 mL conical centrifuge tube and 
the total volume determined. A 20 μL aliquot of the exudate was used to determine the total leucocyte 
count in Neubauer chambers. 
3.12. Calculus and Statistical Analysis 
Data are expressed as mean ± S.E.M. Statistical significance was determined by one-way analysis 
of variance followed by the Student–Newman–Keuls test. P  values below 0.05 were considered 
significant. The percentage of inhibition was calculated by using 
100 − T × 100/C(%) or T × 100/C − 100(%) 
where C and T indicate non-treated (vehicle) and drug-treated, respectively. 
4. Conclusions 
The present study demonstrated that the completion of additional experiments in the investigation 
of the antinociceptive and anti-inflammatory activities of V. condensata allowed a better understanding 
of the central and peripheral mechanisms involved. The results support the popular use of this plant, 
but phytochemical studies together with pharmacological and toxicological investigations have proven 
essential for the complete understanding of their medicinal application.  
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